MARKET

TBIO

TBIO

TRANSLATE BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.13
+0.49
+3.88%
After Hours: 13.13 0 0.00% 16:00 09/25 EDT
OPEN
12.69
PREV CLOSE
12.64
HIGH
13.20
LOW
12.50
VOLUME
758.69K
TURNOVER
--
52 WEEK HIGH
28.09
52 WEEK LOW
6.80
MARKET CAP
974.82M
P/E (TTM)
-7.5179
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sanofi isn't cutting corners in coronavirus vaccine development despite acceleration, CEO says
"We don't feel pressure. We feel pressure to get it right and maintain the standards and to play a big part in helping people get back to normal," Sanofi CEO Paul Hudson told CNBC.
CNBC.com · 1d ago
Coronavirus Stocks: Can mRNA From Covid Fight Be Used To Cure Cancer?
Investor's Business Daily · 09/17 17:12
Sell Moderna, Analyst Says. Covid Vaccine Competition Is Fierce.
Moderna was first but other programs have caught up and it’s looking as if there will be a surfeit of vaccines, SVBLeerink says.
marketwatch.com · 09/08 13:11
Translate Bio Resumes Enrollment And Dosing In Phase 1/2 Clinical Trial Of MRT5005 In Cystic Fibrosis
LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat
Benzinga · 09/08 11:34
Novavax Posts Good Covid Vaccine Data; Sanofi, GlaxoSmithKline Start First Human Tests
Investor's Business Daily · 09/03 13:17
Translate Bio to Participate in Upcoming Investor Conferences
LEXINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the Company will participate
GlobeNewswire · 09/03 11:30
Sanofi, Regeneron Rheumatoid Arthritis Drug Proves Ineffective Against COVID-19
Sanofi SA (NASDAQ: SNY) announced Tuesday that its rheumatoid arthritis drug Kevzara, developed in partnership with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), isn't effective against COVID-19.
Benzinga · 09/01 08:03
Sanofi Vaccine Partner Translate Bio Cites Antibody Response
An experimental coronavirus vaccine developed by Translate Bio Inc. and French drug giant Sanofi induced high levels of protective neutralizing antibodies in early-stage animal studies, according to a regulatory filing.
Bloomberg · 08/25 16:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBIO. Analyze the recent business situations of TRANSLATE BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBIO stock price target is 31.57 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 161
Institutional Holdings: 68.80M
% Owned: 92.66%
Shares Outstanding: 74.24M
TypeInstitutionsShares
Increased
45
9.03M
New
76
5.96M
Decreased
11
1.69M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Daniel Lynch
President/Chief Executive Officer/Director
Ronald Renaud
Founder/Executive Vice President
Michael Heartlein
Chief Financial Officer/Treasurer
John Schroer
Chief Operating Officer
Paul Burgess
Chief Human Resource Officer
Paula Cloghessy
Chief Technology Officer
Frank DeRosa
Chief Scientific Officer
Richard Wooster
Other
Ann Barbier
Other
Brian Fenton
Independent Director
Daniella Beckman
Independent Director
George Demetri
Independent Director
Jean-Francois Formela
Independent Director
Owen Hughes
Independent Director
Robert Meyer
Independent Director
Robert Plenge
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TBIO
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Translate Bio Inc stock information, including NASDAQ:TBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBIO stock methods without spending real money on the virtual paper trading platform.